Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1995 Sep;2(5):574–582. doi: 10.1128/cdli.2.5.574-582.1995

Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease.

D M Granoff 1, S K Kelsey 1, H A Bijlmer 1, L Van Alphen 1, J Dankert 1, R E Mandrell 1, F H Azmi 1, R J Scholten 1
PMCID: PMC170202  PMID: 8548537

Abstract

We measured antibody responses to meningococcal serogroup B (MenB) polysaccharide (PS) by enzyme-linked immunosorbent assay (ELISA) in sera from 94 patients from The Netherlands with disease caused by Neisseria meningitidis group B. The patients ranged in age from 3 to 73 years (mean age, 18.8 years). In initial studies we showed that the binding of a panel of MenB PS-reactive human immunoglobulin M (IgM) paraproteins to biotinylated MenB PS bound to avidin-coated microtiter wells was inhibited > 90% by the addition of soluble MenB PS or encapsulated group B meningococci. In contrast, inhibition of IgM anti-MenB PS antibody-binding activity in many of the patient sera was less than 50% (range, 20 to 94%). These data suggested a high frequency of nonspecific binding in the patient sera. Therefore, all serum samples were assayed in replicate in the presence or absence of soluble MenB PS, and only the inhibitable fraction of the binding signal was used to calculate the anti-MenB PS antibody concentrations. In 17 control patients with meningococcal disease caused by serogroup A or C strains, there was no significant difference in the respective IgM or IgG anti-MenB PS antibody concentrations in paired acute- and convalescent-phase sera. In contrast, in patients with MenB disease, the geometric mean IgM anti-MenB PS antibody concentration increased from 3.9 units/ml in acute-phase serum to 10.5 units/ml in convalescent-phase serum (P < 0.001). The corresponding geometric mean IgG anti-MenB PS antibody titers were 1:27 and 1:36 (P < 0.05). There was only a weak relationship between age and the magnitude of the logarithm of the antibody concentrations in convalescent-phase sera (for IgM, r2 = 0.06 and P < 0.05; for IgG, r2 = 0.08 and P < 0.01). Our data indicate that precautions are needed to avoid nonspecificity in measuring serum antibody responses to MenB PS by ELISA. Furthermore, although this PS is thought to be a poor immunogen, patients as young as 3 years of age recovering from MenB disease demonstrate both ImG and IgG antibody responses in serum.

Full Text

The Full Text of this article is available as a PDF (304.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Artenstein M. S., Brandt B. L., Tramont E. C., Branche W. C., Jr, Fleet H. D., Cohen R. L. Serologic studies of meningococcal infection and polysaccharide vaccination. J Infect Dis. 1971 Sep;124(3):277–288. doi: 10.1093/infdis/124.3.277. [DOI] [PubMed] [Google Scholar]
  2. Azmi F. H., Lucas A. H., Raff H. V., Granoff D. M. Variable region sequences and idiotypic expression of a protective human immunoglobulin M antibody to capsular polysaccharides of Neisseria meningitidis group B and Escherichia coli K1. Infect Immun. 1994 May;62(5):1776–1786. doi: 10.1128/iai.62.5.1776-1786.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Azmi F. H., Lucas A. H., Spiegelberg H. L., Granoff D. M. Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain. Infect Immun. 1995 May;63(5):1906–1913. doi: 10.1128/iai.63.5.1906-1913.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baker C. J., Griffiss J. M. Influence of age on serogroup distribution of endemic meningococcal disease. Pediatrics. 1983 Jun;71(6):923–926. [PubMed] [Google Scholar]
  5. Berger U., Sonntag H. G., Ulbrich C. Epidemiology of meningococcal infections in the Federal Republic of Germany, 1966-1984. Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Mar;268(1):83–102. doi: 10.1016/s0176-6724(88)80118-4. [DOI] [PubMed] [Google Scholar]
  6. Bjune G., Høiby E. A., Grønnesby J. K., Arnesen O., Fredriksen J. H., Halstensen A., Holten E., Lindbak A. K., Nøkleby H., Rosenqvist E. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991 Nov 2;338(8775):1093–1096. doi: 10.1016/0140-6736(91)91961-s. [DOI] [PubMed] [Google Scholar]
  7. Brandt B. L., Wyle F. A., Artenstein M. S. A radioactive antigen-binding assay for Neisseria meningitidis polysaccharide antibody. J Immunol. 1972 Apr;108(4):913–920. [PubMed] [Google Scholar]
  8. Cadoz M., Armand J., Arminjon F., Gire R., Lafaix C. Tetravalent (A, C, Y, W 135) meningococcal vaccine in children: immunogenicity and safety. Vaccine. 1985 Sep;3(3):340–342. doi: 10.1016/s0264-410x(85)90266-x. [DOI] [PubMed] [Google Scholar]
  9. Carlone G. M., Frasch C. E., Siber G. R., Quataert S., Gheesling L. L., Turner S. H., Plikaytis B. D., Helsel L. O., DeWitt W. E., Bibb W. F. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol. 1992 Jan;30(1):154–159. doi: 10.1128/jcm.30.1.154-159.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Finne J., Leinonen M., Mäkelä P. H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983 Aug 13;2(8346):355–357. doi: 10.1016/s0140-6736(83)90340-9. [DOI] [PubMed] [Google Scholar]
  11. Frasch C. E., Zahradnik J. M., Wang L. Y., Mocca L. F., Tsai C. M. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine. J Infect Dis. 1988 Oct;158(4):710–718. doi: 10.1093/infdis/158.4.710. [DOI] [PubMed] [Google Scholar]
  12. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–1326. doi: 10.1084/jem.129.6.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969 Jun 1;129(6):1327–1348. doi: 10.1084/jem.129.6.1327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Goldschneider I., Lepow M. L., Gotschlich E. C. Immunogenicity of the group A and group C meningococcal polysaccharides in children. J Infect Dis. 1972 May;125(5):509–519. doi: 10.1093/infdis/125.5.509. [DOI] [PubMed] [Google Scholar]
  15. Goldschneider I., Lepow M. L., Gotschlich E. C., Mauck F. T., Bachl F., Randolph M. Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J Infect Dis. 1973 Dec;128(6):769–776. doi: 10.1093/infdis/128.6.769. [DOI] [PubMed] [Google Scholar]
  16. Gotschlich E. C., Goldschneider I., Artenstein M. S. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med. 1969 Jun 1;129(6):1385–1395. doi: 10.1084/jem.129.6.1385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Griffiss J. M. Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera. J Immunol. 1975 Jun;114(6):1779–1784. [PubMed] [Google Scholar]
  18. Griffiss J. M., Brandt B. L., Broud D. D., Goroff D. K., Baker C. J. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis. 1984 Jul;150(1):71–79. doi: 10.1093/infdis/150.1.71. [DOI] [PubMed] [Google Scholar]
  19. Hankins W. A., Gwaltney J. M., Jr, Hendley J. O., Farquhar J. D., Samuelson J. S. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135. Proc Soc Exp Biol Med. 1982 Jan;169(1):54–57. doi: 10.3181/00379727-169-41306. [DOI] [PubMed] [Google Scholar]
  20. Hoare D. G., Koshland D. E., Jr A method for the quantitative modification and estimation of carboxylic acid groups in proteins. J Biol Chem. 1967 May 25;242(10):2447–2453. [PubMed] [Google Scholar]
  21. Jackson L. A., Tenover F. C., Baker C., Plikaytis B. D., Reeves M. W., Stocker S. A., Weaver R. E., Wenger J. D. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. Meningococcal Disease Study Group. J Infect Dis. 1994 Feb;169(2):438–441. doi: 10.1093/infdis/169.2.438. [DOI] [PubMed] [Google Scholar]
  22. Jennings H. J., Gamian A., Ashton F. E. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J Exp Med. 1987 Apr 1;165(4):1207–1211. doi: 10.1084/jem.165.4.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Jennings H. J., Gamian A., Michon F., Ashton F. E. Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1. J Immunol. 1989 May 15;142(10):3585–3591. [PubMed] [Google Scholar]
  24. Kabat E. A., Nickerson K. G., Liao J., Grossbard L., Osserman E. F., Glickman E., Chess L., Robbins J. B., Schneerson R., Yang Y. H. A human monoclonal macroglobulin with specificity for alpha(2----8)-linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA. J Exp Med. 1986 Aug 1;164(2):642–654. doi: 10.1084/jem.164.2.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kasper D. L., Winkelhake J. L., Brandt B. L., Artenstein M. S. Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis. J Infect Dis. 1973 Apr;127(4):378–387. doi: 10.1093/infdis/127.4.378. [DOI] [PubMed] [Google Scholar]
  26. Käyhty H., Karanko V., Peltola H., Sarna S., Mäkelä P. H. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis. 1980 Dec;142(6):861–868. doi: 10.1093/infdis/142.6.861. [DOI] [PubMed] [Google Scholar]
  27. Lackie P. M., Zuber C., Roth J. Polysialic acid and N-CAM localisation in embryonic rat kidney: mesenchymal and epithelial elements show different patterns of expression. Development. 1990 Nov;110(3):933–947. doi: 10.1242/dev.110.3.933. [DOI] [PubMed] [Google Scholar]
  28. Leinonen M., Frasch C. E. Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay. Infect Immun. 1982 Dec;38(3):1203–1207. doi: 10.1128/iai.38.3.1203-1207.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lepow M. L., Beeler J., Randolph M., Samuelson J. S., Hankins W. A. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis. 1986 Dec;154(6):1033–1036. doi: 10.1093/infdis/154.6.1033. [DOI] [PubMed] [Google Scholar]
  30. Mandrell R. E., Zollinger W. D. Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants. J Immunol. 1982 Nov;129(5):2172–2178. [PubMed] [Google Scholar]
  31. Norden C. W. Prevalence of bactericidal antibodies to Haemophilus influenzae, type b. J Infect Dis. 1974 Nov;130(5):489–494. doi: 10.1093/infdis/130.5.489. [DOI] [PubMed] [Google Scholar]
  32. O'Reilly R. J., Anderson P., Ingram D. L., Peter G., Smith D. H. Circulating polyribophosphate in Hemophilus influenzae, type b meningitis. Correlation with clinical course and antibody response. J Clin Invest. 1975 Oct;56(4):1012–1022. doi: 10.1172/JCI108148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Peltola H., Safary A., Käyhty H., Karanko V., André F. E. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics. 1985 Jul;76(1):91–96. [PubMed] [Google Scholar]
  34. Raff H. V., Bradley C., Brady W., Donaldson K., Lipsich L., Maloney G., Shuford W., Walls M., Ward P., Wolff E. Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1. J Infect Dis. 1991 Feb;163(2):346–354. doi: 10.1093/infdis/163.2.346. [DOI] [PubMed] [Google Scholar]
  35. Raff H. V., Devereux D., Shuford W., Abbott-Brown D., Maloney G. Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections. J Infect Dis. 1988 Jan;157(1):118–126. doi: 10.1093/infdis/157.1.118. [DOI] [PubMed] [Google Scholar]
  36. Reingold A. L., Broome C. V., Hightower A. W., Ajello G. W., Bolan G. A., Adamsbaum C., Jones E. E., Phillips C., Tiendrebeogo H., Yada A. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985 Jul 20;2(8447):114–118. doi: 10.1016/s0140-6736(85)90224-7. [DOI] [PubMed] [Google Scholar]
  37. Rosenqvist E., Harthug S., Frøholm L. O., Høiby E. A., Bøvre K., Zollinger W. D. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol. 1988 Aug;26(8):1543–1548. doi: 10.1128/jcm.26.8.1543-1548.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rougon G., Dubois C., Buckley N., Magnani J. L., Zollinger W. A monoclonal antibody against meningococcus group B polysaccharides distinguishes embryonic from adult N-CAM. J Cell Biol. 1986 Dec;103(6 Pt 1):2429–2437. doi: 10.1083/jcb.103.6.2429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schneider H., Griffiss J. M., Williams G. D., Pier G. B. Immunological basis of serum resistance of Neisseria gonorrhoeae. J Gen Microbiol. 1982 Jan;128(1):13–22. doi: 10.1099/00221287-128-1-13. [DOI] [PubMed] [Google Scholar]
  41. Scholten R. J., Bijlmer H. A., Valkenburg H. A., Dankert J. Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect. 1994 Feb;112(1):115–124. doi: 10.1017/s0950268800057472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Skevakis L., Frasch C. E., Zahradnik J. M., Dolin R. Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis. J Infect Dis. 1984 Mar;149(3):387–396. doi: 10.1093/infdis/149.3.387. [DOI] [PubMed] [Google Scholar]
  43. Stephens D. S., Swartley J. S., Kathariou S., Morse S. A. Insertion of Tn916 in Neisseria meningitidis resulting in loss of group B capsular polysaccharide. Infect Immun. 1991 Nov;59(11):4097–4102. doi: 10.1128/iai.59.11.4097-4102.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sutton A., Vann W. F., Karpas A. B., Stein K. E., Schneerson R. An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides. J Immunol Methods. 1985 Oct 10;82(2):215–224. doi: 10.1016/0022-1759(85)90353-9. [DOI] [PubMed] [Google Scholar]
  45. WHITE L. A., KELLOGG D. S., Jr NEISSERIA GONORRHOEAE IDENTIFICATION IN DIRECT SMEARS BY A FLUORESCENT ANTIBODY-COUNTERSTAIN METHOD. Appl Microbiol. 1965 Mar;13:171–174. doi: 10.1128/am.13.2.171-174.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Zollinger W. D., Boslego J., Moran E., Garcia J., Cruz C., Ruiz S., Brandt B., Martinez M., Arthur J., Underwood P. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. The Chilean National Committee for Meningococcal Disease. NIPH Ann. 1991 Dec;14(2):211–213. [PubMed] [Google Scholar]
  47. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979 May;63(5):836–848. doi: 10.1172/JCI109383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Zollinger W. D., Mandrell R. E. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun. 1983 Apr;40(1):257–264. doi: 10.1128/iai.40.1.257-264.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Zollinger W. D., Pennington C. L., Artenstein M. S. Human antibody response to three meningococcal outer membrane antigens: comparison by specific hemagglutination assays. Infect Immun. 1974 Nov;10(5):975–984. doi: 10.1128/iai.10.5.975-984.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. de Marie S., Poolman J. T., Hoeijmakers J. H., Bol P., Spanjaard L., Zanen H. C. Meningococcal disease in The Netherlands, 1959-1981: the occurrence of serogroups and serotypes 2a and 2b of Neisseria meningitidis. J Infect. 1986 Mar;12(2):133–143. doi: 10.1016/s0163-4453(86)93583-8. [DOI] [PubMed] [Google Scholar]
  51. de Moraes J. C., Perkins B. A., Camargo M. C., Hidalgo N. T., Barbosa H. A., Sacchi C. T., Landgraf I. M., Gattas V. L., Vasconcelos H. de G., Gral I. M. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992 Oct 31;340(8827):1074–1078. doi: 10.1016/0140-6736(92)93086-3. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES